Reply to E.A. Rakha et al
- PMID: 25753441
- DOI: 10.1200/JCO.2014.59.7559
Reply to E.A. Rakha et al
Comment on
-
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7. J Clin Oncol. 2013. PMID: 24101045
-
National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer.J Clin Oncol. 2015 Apr 10;33(11):1301-2. doi: 10.1200/JCO.2014.59.7211. Epub 2015 Mar 9. J Clin Oncol. 2015. PMID: 25753440 No abstract available.
Similar articles
-
National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer.J Clin Oncol. 2015 Apr 10;33(11):1301-2. doi: 10.1200/JCO.2014.59.7211. Epub 2015 Mar 9. J Clin Oncol. 2015. PMID: 25753440 No abstract available.
-
American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents.Arch Pathol Lab Med. 2015 Aug;139(8):970-1. doi: 10.5858/arpa.2015-0074-ED. Epub 2015 Apr 17. Arch Pathol Lab Med. 2015. PMID: 25884371 No abstract available.
-
Reply to Ki67 in breast cancer: a useful prognostic marker!Ann Oncol. 2014 Feb;25(2):542-3. doi: 10.1093/annonc/mdt564. Epub 2014 Jan 15. Ann Oncol. 2014. PMID: 24431345 No abstract available.
-
Precision medicine in breast cancer.Chin Clin Oncol. 2018 Jun;7(3):29. doi: 10.21037/cco.2018.06.04. Chin Clin Oncol. 2018. PMID: 30056731 Review.
-
De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.Pharmacogenomics. 2015;16(12):1411-26. doi: 10.2217/pgs.15.88. Epub 2015 Aug 10. Pharmacogenomics. 2015. PMID: 26257318 Review.
Cited by
-
Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options.Breast Cancer (Auckl). 2024 Feb 25;18:11782234241234418. doi: 10.1177/11782234241234418. eCollection 2024. Breast Cancer (Auckl). 2024. PMID: 38410761 Free PMC article. Review.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer.Cancers (Basel). 2019 Jul 28;11(8):1067. doi: 10.3390/cancers11081067. Cancers (Basel). 2019. PMID: 31357743 Free PMC article.
-
[Update of the German S3 breast cancer guideline : What is new for pathologists?].Pathologe. 2019 Mar;40(2):185-198. doi: 10.1007/s00292-019-0578-3. Pathologe. 2019. PMID: 30847505 German.
-
HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.Mod Pathol. 2017 Nov;30(11):1561-1566. doi: 10.1038/modpathol.2017.65. Epub 2017 Jul 28. Mod Pathol. 2017. PMID: 28752841
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical